Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89.
Strontium-89 (89Sr) is currently used for the treatment of painful bone metastases. This study reports the use of low-dose carboplatin as a radiosensitizer in 89Sr radioisotope therapy. The study design comprised two groups: 15 patients treated with 89Sr (148 MBq) followed by carboplatin (100 mg m-2 at 7 and 21 days) and 15 patients treated with 89Sr alone. Their pain response was assessed 8 weeks post-injection. Follow-up was continued for up to 1 year in the survivors. Twenty-seven patients were evaluable. A pain response was observed in 20 of 27 (74%) patients. The pain response in the patients treated with 89Sr and carboplatin was clearly superior to that seen in the patients treated with 89Sr alone (P = 0.025), whereas survival was only marginally better in the combined treatment group (8.1 vs 5.7 months, P = 0.19). No clinically significant adverse effects or myelosuppression by carboplatin were observed. Low-dose carboplatin enhances the effects of 89Sr radioisotope therapy on pain from bone metastases.
Sciuto
R
R
Department of Nuclear Medicine, Regina Elena Cancer Institute, Rome, Italy.
Maini
C L
CL
Tofani
A
A
Fiumara
C
C
Scelsa
M G
MG
Broccatelli
M
M
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D001943:Breast Neoplasms; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000532:radiotherapy*; D010166:Palliative Care / Q000379:methods*; D011471:Prostatic Neoplasms; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D013326:Strontium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
D011838:Radiation-Sensitizing Agents; D013326:Strontium Radioisotopes; D016190:Carboplatin